A novel polio vaccine that does not require refrigeration could someday be used all over the world to deliver the final blow to the contagious disease that mainly affects children under five years of age, say researchers.
The injectable vaccine, developed by researchers from the University of Southern California (USC) is freeze-dried into a powder and can be kept at room temperature for four weeks, which can then be rehydrated.
When tested in mice, the novel vaccine offered full protection against the polio virus, the researchers said.
The study appears in the journal mBio.
By removing moisture through freeze-drying, researchers have created temperature-stable vaccines for measles, typhoid and meningococcal disease. But scientists have not been able to make a polio vaccine that retains potency through freeze-drying and rehydration.
They now hope that a foundation or company will take over the project to pay for human studies and bring the injectable vaccine onto the market.
Yet in countries where vaccination rates are spotty, young children are at risk.
The biggest hitch to complete eradication has been creating a temperature-stable vaccine for use in developing countries where refrigeration may be unavailable. Recent polio cases have been reported in Nigeria, Papua New Guinea, Syria and Pakistan.
(At The Quint, we are answerable only to our audience. Play an active role in shaping our journalism by becoming a member. Because the truth is worth it.)